fig2
From: EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
Figure 2. Immunoblot of BRAF/MEK/ERF signaling axis and activated AKT in the TNBC cell line panel. TNBC: triple negative breast cancer; AKT: protein kinase B
